TA Announces Advantive, a New Mission-Critical Software Provider for Specialty Manufacturing and Distribution Businesses
28.6.2022 16:13:00 EEST | Business Wire | Press release
TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/
Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida.
Benoit de la Tour, an accomplished executive in the ERP and Supply Chain software space, has been named the CEO of Advantive. “I'm thrilled to join Advantive as CEO, working hand-in-hand with TA and ST6 to deliver increased customer value,” said Benoit. “Advantive was formed with a simple purpose— to drive sustainable growth for specialty manufacturing and distribution companies. We’re in a unique position, alongside our customers, to make a real impact. With Advantive’s packaging, ecommerce and delivery solutions, spanning raw resources to valuable products, we’re transforming the manufacturing and distribution lifecycle.”
“We are excited to partner with Benoit and ST6 as we build upon the strength of Advantive’s constituent businesses to create an overall market leader in ERP, MES and SPC software,” said Hythem El-Nazer, a Managing Director at TA. “Advantive’s software solutions modernize and optimize every aspect of the manufacturing and distribution lifecycle, from enhanced plant production, supply chain optimization and ecommerce, to managing quality and compliance. Advantive is changing the way business is done, and we are excited to support the business as it grows.”
Mark Friedman, a longtime, experienced software operating executive and investor, is the Executive Chairman of Advantive. Friedman, currently a Managing Director at ST6, was previously the founder and CEO of Accruent, a leading software company that disrupted the multi-billion-dollar facilities management and lease administration software market. “Now more than ever, our customers need the ability to rapidly adapt to global supply chain challenges, and to gain a competitive advantage,” said Friedman. “By combining the strengths of Advantive’s constituent companies, and delivering deep, purpose-built software, we believe we are positioned to drive transformational outcomes for our customers.’
About Advantive
Advantive is a market leader in mission-critical software for specialty manufacturing and distribution companies, offering purpose-built ERP, MES and SPC software solutions that meet the unique needs of our customers. Serving over 2,500 customers and operating in 8 countries, Advantive’s software solutions streamline complex processes, optimize operations visibility and throughput, and drive improved quality, profitability and revenue growth. Deeply embedded into key end-to-end workflows, Advantive’s software uses automation, seamless integration and real-time data to streamline plant scheduling, order management, quality control, sales order forecasting and pricing, ecommerce and delivery – making the complex, simple.
About TA
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer, and business services – the firm invests in profitable, growing companies with opportunities for sustained growth and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .
About ST6
ST6 is an elite team of software operating executives that partner with private equity sponsors to transform software companies and accelerate value creation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005803/en/
Contact information
MEDIA:
Jeff Sindone
Teneo
Jeff.Sindone@teneo.com
Mobile: (917) 224-7140
Maggie Benoit
TA
mbenoit@ta.com
Office: 617-598-6685
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
